APA (7th ed.) Citation

H, K., T, M., Y, I., T, S., K, H., Y, N., . . . K, M. (2026). Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: A case report. Therapeutic advances in medical oncology, 18, 17588359261451859. https://doi.org/10.1177/17588359261451859

Chicago Style (17th ed.) Citation

H, Kodama, et al. "Response to Nivolumab as an Immune Checkpoint Inhibitor Rechallenge for Esophageal Squamous Cell Carcinoma with PD-L1 Amplification: A Case Report." Therapeutic Advances in Medical Oncology 18 (2026): 17588359261451859. https://doi.org/10.1177/17588359261451859.

MLA (9th ed.) Citation

H, Kodama, et al. "Response to Nivolumab as an Immune Checkpoint Inhibitor Rechallenge for Esophageal Squamous Cell Carcinoma with PD-L1 Amplification: A Case Report." Therapeutic Advances in Medical Oncology, vol. 18, 2026, p. 17588359261451859, https://doi.org/10.1177/17588359261451859.